GlaxoSmithKline (GSK) Earns “Neutral” Rating from J P Morgan Chase & Co
J P Morgan Chase & Co reissued their neutral rating on shares of GlaxoSmithKline (LON:GSK) in a research note issued to investors on Wednesday morning. J P Morgan Chase & Co currently has a GBX 1,330 ($17.90) price objective on the stock.
Several other equities analysts also recently weighed in on the company. Societe Generale restated a sell rating on shares of GlaxoSmithKline in a research report on Thursday, November 9th. Berenberg Bank decreased their target price on GlaxoSmithKline from GBX 1,835 ($24.70) to GBX 1,760 ($23.69) and set a buy rating on the stock in a research report on Thursday, November 2nd. Morgan Stanley set a GBX 1,450 ($19.52) target price on GlaxoSmithKline and gave the company a sell rating in a research report on Monday, November 6th. Deutsche Bank set a GBX 1,610 ($21.67) target price on GlaxoSmithKline and gave the company a neutral rating in a research report on Friday, October 27th. Finally, Barclays restated an equal weight rating and issued a GBX 1,450 ($19.52) target price on shares of GlaxoSmithKline in a research report on Friday, October 27th. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus price target of GBX 1,562.86 ($21.03).
GlaxoSmithKline (LON:GSK) traded up GBX 4.50 ($0.06) during midday trading on Wednesday, hitting GBX 1,295 ($17.43). The stock had a trading volume of 15,936,631 shares, compared to its average volume of 10,100,000. GlaxoSmithKline has a 1-year low of GBX 1,270 ($17.09) and a 1-year high of GBX 1,724.50 ($23.21).
The company also recently declared a dividend, which will be paid on Thursday, January 11th. Stockholders of record on Thursday, November 9th will be given a dividend of GBX 19 ($0.26) per share. The ex-dividend date is Thursday, November 9th. This represents a dividend yield of 1.41%.
In other news, insider Urs Rohner purchased 473 shares of the stock in a transaction dated Wednesday, October 25th. The stock was acquired at an average cost of GBX 1,518 ($20.43) per share, for a total transaction of £7,180.14 ($9,663.71). Also, insider Simon Dingemans purchased 1,076 shares of the stock in a transaction dated Thursday, October 12th. The shares were purchased at an average price of GBX 1,527 ($20.55) per share, with a total value of £16,430.52 ($22,113.76). Over the last 90 days, insiders have bought 1,577 shares of company stock valued at $2,400,086.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.